Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. ONIVYDE (chlorhydrate d’irinotécan trihydrate liposomal pégylé)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

ONIVYDE (chlorhydrate d’irinotécan trihydrate liposomal pégylé)

Medicine - Posted on Jun 30 2025
Active substance (DCI)
  • irinotécan liposomal pégylé
history (2)
  • 6/11/25

    ONIVYDE PEGYLATED LIPOSOMAL (irinotécan liposomal pégylé) - Cancer du pancréas métastatique

    Inscription L'essentiel Avis favorable au remboursement d’ONIVYDE PEGYLATED LIPOSOMAL « en association avec l'oxaliplatine, ...
    CAV :
    54321
    icône flèche
  • 4/19/17

    ONIVYDE (pegylated liposomal irinotecan), antineoplastic agent

    No clinical benefit demonstrated in the treatment of metastatic pancreatic adenocarcinoma. ONIVYDE has marketing authorisati...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01CE02
Manufacturer
LES LABORATOIRES SERVIER
Presentation

ONIVYDE 5 mg/ml, solution à diluer pour perfusion (code CIS : 63390752) 
1 flacon en verre de 10 ml (CIP : 34009 300 741 5 2)

All our publications
    Digestive system cancers Drug therapy Pancreatic and biliary tract diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
BdRYYfCUV1jRDTVf